Cargando…

A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study’

Detalles Bibliográficos
Autores principales:	Chen, Yuan, Wang, Chengcheng, Zhao, Yupei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583943/ https://www.ncbi.nlm.nih.gov/pubmed/37402310 http://dx.doi.org/10.1097/JS9.0000000000000588

Ejemplares similares

The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
por: Su, Yung-Yeh, et al.
Publicado: (2023)

An invited commentary on ‘Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study’
por: Coppola, Alessandro, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
por: Ghanem, I., et al.
Publicado: (2022)

Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis
por: Bradley, Alison, et al.
Publicado: (2019)

A commentary on ‘Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection’
por: Xu, Ruiyuan, et al.
Publicado: (2023)

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2022)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

A commentary on ‘Detection of cancer cells and tumor margins during colorectal cancer surgery by intraoperative flow cytometry’
por: Chen, Yuan, et al.
Publicado: (2023)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Jung, Hye-Sol, et al.
Publicado: (2022)

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
por: Ren, Xiaohan, et al.
Publicado: (2019)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
por: Jeon, Hyun Jeong, et al.
Publicado: (2023)

Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis
por: Chen, Xing, et al.
Publicado: (2017)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2019)

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications
por: Deig, Christopher Ryan, et al.
Publicado: (2022)

Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment
por: Fujii, Tsutomu, et al.
Publicado: (2015)

The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer
por: Zwart, Eline S., et al.
Publicado: (2023)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis
por: Wu, Liucheng, et al.
Publicado: (2019)

Upfront surgery in patients with epithelial ovarian cancer and enlarged supradiaphragmatic lymph nodes associated with comparable to neoadjuvant chemotherapy
por: Weitzner, Omer, et al.
Publicado: (2022)

Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
por: Fiflis, Stylianos, et al.
Publicado: (2023)

Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy
por: Famularo, Simone, et al.
Publicado: (2023)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

A commentary on ‘Macrophage morphology and distribution are strong predictors of prognosis in resected colorectal liver metastases: results from an external retrospective observational study’
por: Chen, Yuan, et al.
Publicado: (2023)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials
por: Zhang, Xiao-Nan, et al.
Publicado: (2017)

RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery
por: Fagotti, A, et al.
Publicado: (2016)

Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
por: Yang, Zijiao, et al.
Publicado: (2023)

The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases
por: Altman, Ariella M., et al.
Publicado: (2022)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study
por: Li, Yang, et al.
Publicado: (2020)

Responses to commentary on ‘Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis’ (Int J Surg 2022;106:106929)
por: Wang, Zhaoyang, et al.
Publicado: (2023)

Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients
por: Han, Myung Hyun, et al.
Publicado: (2019)

A commentary on ‘Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis’
por: Cheng, Kunming, et al.
Publicado: (2023)

Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol
por: McCarthy, Amy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mh02i2gvh95vpc25mbjqeld5nv